All News
Filter News
Found 216 articles
-
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results
11/8/2021
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the third quarter ended September 30, 2021.
-
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 8th
11/1/2021
Avadel Pharmaceuticals plc announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, November 8, 2021, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2021.
-
Avadel Presents New Data Supporting Clinical Benefit with Once-at-Bedtime FT218 and Preference for Once-Nightly Dosing in Patients with Narcolepsy at CHEST 2021
10/19/2021
Avadel Pharmaceuticals plc today announced new data from the completed pivotal Phase 3 REST-ON clinical trial of FT218, also known as ON-SXB.
-
Avadel Pharmaceuticals Announces Ongoing FDA Review of NDA for FT218 for Patients with Narcolepsy
10/15/2021
Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that the U.S. Food and Drug Administration notified the company that the review of the New Drug Application for FT218 is still ongoing, and action will likely not be taken in October.
-
The U.S. FDA is kicking off the month of October with a number of PDUFA dates and an advisory committee meeting. Read on for more details.
-
Idiopathic hypersomnia (IH) Treatment Market Analysis and Opportunity Assessment up to 2031
9/23/2021
Idiopathic hypersomnia (IH) is a chronic neurologic disorder marked by an insatiable need to sleep that is not eased by a full night’s slumber.
-
Avadel Recognizes World Narcolepsy Day and Announces New Data Presentations from Pivotal Phase 3 REST-ON Trial of FT218 at Upcoming Conference
9/20/2021
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced its support of the third annual World Narcolepsy Day on Wednesday, September 22.
-
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021
9/2/2021
Avadel Pharmaceuticals plc, a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming virtual investor conferences in September:
-
Clinical Catch-Up: August 16-20
8/23/2021
It was another busy week in clinical trial news. Here’s a look. -
Narcolepsy Drugs Market Asia Pacific has shown large potential and is anticipated to rise at rapid growth rate to 2028
8/20/2021
The narcolepsy drug pipeline has been dotted with medications that can target several symptoms of neurological sleep disorder.
-
Avadel Pharmaceuticals Announces Publication of Data from Pivotal Phase 3 REST-ON Trial of FT218 in Adults with Narcolepsy in SLEEP
8/16/2021
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, announced today the publication of data from its pivotal Phase 3 REST-ON trial of FT218 in SLEEP, the journal of the Sleep Research Society.
-
Antidiuretic Drugs Market Detailed Study Analysis with Accurate Forecast to 2028
8/16/2021
The global market for antidiuretic drugs has been rising on account of advancements in the field of pharmaceutical formulations.
-
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results
8/9/2021
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2021.
-
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th
8/2/2021
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company primarily focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 9, 2021, t
-
Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
7/7/2021
Avadel Pharmaceuticals plc announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat on Wednesday, July 14 at 11:00 a.m. ET.
-
Myasthenia Gravis Market: Rapid Immunotherapies Segment to Dominate the Market
6/22/2021
Transparency Market Research has published a new report titled, ‘Myasthenia Gravis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.
-
Clinical Catch-Up: June 7-11
6/14/2021
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more. -
BioSpace Movers & Shakers, June 4
6/4/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. -
Avadel to Present New Efficacy and Safety Data from Pivotal Phase 3 REST-ON Trial of FT218 at SLEEP 2021
6/3/2021
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced it will present primary and secondary endpoint data, including new post hoc analyses, from the pivotal Phase 3 REST-ON clinical trial at SLEEP 2021, at the 35th Annual Meeting
-
Avadel Pharmaceuticals Expands Leadership Team with Three Strategic Hires
6/2/2021
Bolsters team with addition of established biopharma industry leaders in advance of anticipated regulatory approval and commercialization of once-nightly FT218 for narcolepsy